A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Financial Summary
| Share Statistics | SCNI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.1 | $252.6 | 1% |
|
| Shares Out (Mil) | 3.1 | 52.3 | 10% |
|
| Institutional Ownership | 6.4% | 92.1% | 6% |
|
| Float (Mil) | 3.9 | 40.2 | 10% |
|
| Beta | 2.05 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 122 | 455 | 38% |
|
| Price Change (52-week) |
(83.0%) | 52.9% | 6% |
|
| Growth | SCNI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (42.8%) | (9.9%) | 9% |
|
| EPS (5yr) | 22.2% | 16.0% | 71 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 81.6% | (15.6%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SCNI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 2% |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 30% |
|
| EPS (TTM) | ($3.558) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($31) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $5 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $5 | 20% |
|
| Enterprise Value (Q1) (Mil) | $9 | $180 | 7% |
|
| Valuation | SCNI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.38 | 2.56 | 6% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SCNI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (329.3%) | 63.8% | 1% |
|
| Net Margin | (261.4%) | (67.3%) | 4% |
|
| ROA | (57.1%) | (49.8%) | 10% |
|
| ROE | 793.8% | (55.5%) | 100% |
|
| Liabilities to Assets | 30.3% | 30.3% | 21% |
|
| F-Score | 2 | 3 | 7% |
|
Scinai Immunotherapeutics Ltd. did not pass any screens on 7/31/2026.
